8/F, 35 QRC Building, No.35 Queens Road, Central, Hong Kong
hkmagicure@gmail.com
CN
4007188120
more

Doctor Introduction

Dr.Azzoli Doctor
MD

Medical School: Johns Hopkins University School of Medicine; Residency: Johns Hopkins Hospital; Fellowship: Memorial Sloan-Kettering Cancer Center;

David White Doctor
MD

Professor of clinical medicine at Harvard Medical School; Chief physician of the Division of Sleep Medicine in the Division of Laboratory Medicine at Harvard Brigham and Women's Hospital.

Jatin P. Shah Doctor
MD

The Elliott W. Strong Chair in Head and Neck Oncology at Memorial Sloan-Kettering Cancer Center in New York City.

Our Services

Hong Kong Magicure Medical Center focuses on the field of precision tumor diagnosis and treatment, and finds the best treatment plan for patients around the world.

Breast Tumor

Our services

Breast Tumor
Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer. The kind of breast cancer depends on which cells in the breast turn into cancer.
more
Urologic System

Our services

Urologic System
Urologic neoplasms occur in tumors anywhere in the urinary system. Including kidney, renal pelvis, ureter, bladder, urethra tumors.
more
Respiratory System

Our services

Respiratory System
Asthma is divided into two types: exogenous and endogenous. Exogenous asthma mainly refers to allergic asthma; endogenous asthma mainly refers to non-allergic asthma.
more
Blood Tumor

Our services

Blood Tumor
Common hematological tumors include various types of leukemia, multiple myeloma and malignant lymphoma.
more
Rare Disease

Our services

Rare Disease
Rare diseases are those diseases with very low incidence. Rare diseases, also known as "orphan diseases", do not have a clear definition in China.
more

Popular Drugs

more

All Medicines

Enhertu (fam trastuzumab deruxt
Version: Hong Kong
Manufacturer: Daiichi Sankyo
Lorlatinib (Lorbrena)
Version: America
Manufacturer: Pfizer Inc.
Aduhelm (Aducanumab)
Version: U.K.
Manufacturer: Biogen Inc.
Tepmetko (Tepotinib)
Version: Germany
Manufacturer: Merck
Dupixent (Dupilumab)
Version: America
Manufacturer: Regeneron
Kerendia (Finerenone)
Version: Germany
Manufacturer: Bayer
more

Lectures

News

more

Phase 3 trial of Dupixent (dupi

Author: Magicure Date: 2023-03-20

On March 18 / hkmagicure , Regeneron and Sanofi presented positive results from the clinical trial assessing Dupixent (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermati...

more

  • 11:2 wins! FDA ODAC Supports Ph

    Author: Magicure Date: 2023-03-10

    On March 10, Roche announced that the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 in favour of Polivy (polatuzumab vedotin-piiq) i...

  • The marketing application of Du

    Author: Magicure Date: 2023-03-08

    On March 7, Regeneron and Sanofi announced that the U.S. FDA has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent...

  • Phase 2 Clinical Trial Data of

    Author: Magicure Date: 2023-03-07

    On March 6, Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZen...

  • CDK4/6 Inhibitor Verzenio Recei

    Author: Magicure Date: 2023-03-06

    On March 3, Lilly announced that the U.S. FDA approved an expanded indication for Verzenio (abemaciclib), in combination with endocrine therapy (ET), f...

  • Trodelvy (sacituzumab govitecan

    Author: Magicure Date: 2023-02-21

    On February 17, Gilead announced new and updated positive results from three cohorts of the Phase 2 TROPHY-U-01 study of Trodelvy (sacituzumab goviteca...

  • Trodelvy Approved by FDA for Me

    Author: Magicure Date: 2023-02-09

    Trodelvy (Sacituzumab Govitecan-hziy) is approved drug for the treatment of metastatic triple-negative breast cancer (mTNBC). It is a type of immunothe...

  • FDA approved Trodelvy for HR+/H

    Author: Magicure Date: 2023-02-06

    The Food and Drug Administration (FDA) approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of patients with unresectable (not eligible to ...

  • “First in class” Targeted d

    Author: Magicure Date: 2023-02-03

    On February 2, AstraZeneca and Amgen announced the U.S. FDA has approved Tezspire (tezepelumab) for self-administration in a pre-filled, single-use pen...

About Magicure

Hong Kong Magicure Medical Center has long been focusing on the import and export of new drugs, special drugs and rare disease drugs in the field of oncology. At the same time, the medical center cooperates with a number of medical institutions in China and Hong Kong, and is committed to providing customers with efficient, convenient and safe medical services.

As an enterprise dedicated to providing safe, reliable and reassuring drugs for chronic diseases to hospitals, pharmacies and patients, Hong Kong Magicure Medical Co., Ltd. has always adhered to the business and sales tenet of honest management and attentive service and "focusing on oncology drugs and continuous improvement" The concept of "patient health", and strive to meet the medication needs of different hospitals, pharmacies and patients.

more
Qualification Contact Us

4007188120

8/F, 35 QRC Building, No.35 Queens Road, Central, Hong Kong

hkmagicure@gmail.com

Magicure

Our Services

Links

Follow us

Hot search keywords： Enhertu Tukysa Tabrecta Genentech Breast Cance Breast Cance Breast Cance Novartis Breast Cance Breast Cance
Copyright © 2022 Hong Kong Magicure Medical Center All rights reserved.